SHINE appoints Michael Rossi as CEO of SHINE SPECT USA following Lantheus acquisition

SHINE announced that it has completed its acquisition of Lantheus' SPECT business, including the North Billerica, Massachusetts SPECT manufacturing facility and its portfolio of diagnostic radiopharmaceuticals. The acquisition brings immediate revenue and operational scale in the $19 billion nuclear medicine market. SHINE also announced that Michael Rossi will join the company as CEO of SHINE SPECT USA, LLC.

The acquisition integrates manufacturing expertise, customer relationships, and established market position into SHINE's nuclear medicine business.

"The nuclear medicine supply chain needs to be modernized to keep up with patient needs," says Greg Piefer, founder and CEO SHINE Technologies. "We're building that now, bringing new technology to bear across both diagnostic and therapeutic markets. This strengthens the entire isotope supply ecosystem and positions SHINE to deliver the reliability healthcare depends on."

To lead the integration and growth of the SPECT business, SHINE has named Michael Rossi as CEO of SHINE SPECT USA, LLC.

Most recently, Rossi served as President and CEO of Y-mAbs Therapeutics, where he led the company's growth and successful acquisition by SERB Pharmaceuticals. He was General Manager of the U.S. business for Advanced Accelerator Applications, a Novartis company, and served as GM of GE Healthcare's Global SPECT Segment. He also led Jubilant Radiopharma as President, building it into a vertically integrated radiopharmaceutical leader. Rossi currently serves on the Board of Directors for Nucleus RadioPharma.

"Mike Rossi's thirty years of experience in radiopharmaceuticals makes him the right leader to integrate and grow our SPECT operations," said Piefer.

"I'm excited to join SHINE at this pivotal moment. The SPECT team has built strong customer relationships and operational excellence over decades. Combining that foundation with SHINE's expanding production capabilities creates the integrated platform the nuclear medicine market needs. I'm looking forward to working with this team to strengthen supply chain security for our customers and patients," said Michael Rossi.

SHINE's Chrysalis facility, currently under development in Janesville, Wisconsin, is designed to become the largest isotope production facility in the world. Chrysalis will use fusion-based technology to produce molybdenum-99 (Mo-99), the parent isotope that decays into Tc-99m used in diagnostic imaging. The SPECT business will use the Mo-99, Xe-133, and other isotopes produced at Chrysalis, creating an integrated supply chain from production through distribution to patients.

With this acquisition, SHINE's nuclear medicine platform now spans both diagnostic and therapeutic applications. The North Billerica SPECT facility, operating as SHINE SPECT USA, LLC, brings decades of SPECT production expertise. SHINE currently operates one of the largest Lu-177 production facilities in the western hemisphere, with capacity for up to 100,000 doses annually and the ability to expand to 200,000 doses per year for targeted cancer therapies. Together, these capabilities position SHINE to deliver integrated isotope supply across the full spectrum of nuclear medicine.